Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis

Current Opinion in Immunology

Volumn 45, Issue , 2017, Pages 8-15

  Méndez Huergo, Santiago P ^a   Blidner, Ada G ^a   Rabinovich, Gabriel A ^a,b  

^a Facultad de Ciencias Naturales e Instituto M Lillo   (Argentina)

^b UNIVERSIDAD DE BUENOS AIRES   (Argentina)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN; GLYCAN;

BONE MARROW CELL; CARCINOGENESIS; CD4+ T LYMPHOCYTE; CELL DIFFERENTIATION; GENE EXPRESSION PROFILING; GLIOBLASTOMA; GLYCOSYLATION; HUMAN; IMMUNOMODULATION; IMMUNOREGULATION; INTERNALIZATION; KAPOSI SARCOMA; NATURAL KILLER CELL; OLIGOMERIZATION; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; REGULATORY T LYMPHOCYTE; REVIEW; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR IMMUNITY; ANIMAL; IMMUNOLOGY; NEOPLASM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; VASCULARIZATION;

ANIMALS; GALECTINS; HUMANS; KILLER CELLS, NATURAL; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; T-LYMPHOCYTES;

EID: 85009152051     PISSN: 09527915     EISSN: 18790372     Source Type: Journal    
DOI: 10.1016/j.coi.2016.12.003     Document Type: Review

References (80)

1. 1 Topalian, S.L., Drake, C.G., Pardoll, D.M., Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell 27 (2015), 450–461.
2. 2 Sharma, P., Allison, J.P., Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161 (2015), 205–214.
3. 3 Anderson, A.C., Joller, N., Kuchroo, V.K., Lag-3, Tim-3, and TIGIT: co-inhibitory receptors with specialized functions in immune regulation. Immunity 44 (2016), 989–1004.
4. 4 Thiemann, S., Baum, L.G., Galectins and immune responses-just how do they do those things they do?. Annu Rev Immunol 34 (2016), 243–264.
5. 5 Rabinovich, G.A., Conejo-Garcia, J.R., Shaping the immune landscape in cancer by galectin-driven regulatory pathways. J Mol Biol 428 (2016), 3266–3281.
6. 6 Rabinovich, G.A., Croci, D.O., Regulatory circuits mediated by lectin–glycan interactions in autoimmunity and cancer. Immunity 36 (2012), 322–335.
7. 7 Dimitroff, C.J., Galectin-binding O-glycosylations as regulators of malignancy. Cancer Res 75 (2015), 3195–3202.
8. 8 Lau, K.S., Partridge, E.A., Grigorian, A., Silvescu, C.I., Reinhold, V.N., Demetriou, M., Dennis, J.W., Complex N-glycan number and degree of branching cooperate to regulate cell proliferation and differentiation. Cell 129 (2007), 123–134.
9. 9•• Kouo, T., Huang, L., Pucsek, A.B., Cao, M., Solt, S., Armstrong, T., Jaffee, E., Galectin-3 shapes antitumor immune responses by suppressing CD8+ T cells via LAG-3 and inhibiting expansion of plasmacytoid dendritic cells. Cancer Immunol Res 3 (2015), 412–423 This study reports the role of galectin-3 as a potent suppressor of CD8+ antitumor T cell responses via direct interaction with the checkpoint molecule LAG-3.
10. 10 Stillman, B.N., Hsu, D.K., Pang, M., Brewer, C.F., Johnson, P., Liu, F.T., Baum, L.G., Galectin-3 and galectin-1 bind distinct cell surface glycoprotein receptors to induce T cell death. J Immunol 176 (2006), 778–789.
11. 11 Starossom, S.C., Mascanfroni, I.D., Imitola, J., Cao, L., Raddassi, K., Hernandez, S.F., Bassil, R., Croci, D.O., Cerliani, J.P., Delacour, D., et al. Galectin-1 deactivates classically activated microglia and protects from inflammation-induced neurodegeneration. Immunity 37 (2012), 249–263.
12. 12 de la Fuente, H., Cruz-Adalia, A., Martinez Del Hoyo, G., Cibrian-Vera, D., Bonay, P., Perez-Hernandez, D., Vazquez, J., Navarro, P., Gutierrez-Gallego, R., Ramirez-Huesca, M., et al. The leukocyte activation receptor CD69 controls T cell differentiation through its interaction with galectin-1. Mol Cell Biol 34 (2014), 2479–2487.
13. 13 Bonzi, J., Bornet, O., Betzi, S., Kasper, B.T., Mahal, L.K., Mancini, S.J., Schiff, C., Sebban-Kreuzer, C., Guerlesquin, F., Elantak, L., Pre-B cell receptor binding to galectin-1 modifies galectin-1/carbohydrate affinity to modulate specific galectin-1/glycan lattice interactions. Nat Commun, 6, 2015, 6194.
14. 14 Zhu, C., Anderson, A.C., Schubart, A., Xiong, H., Imitola, J., Khoury, S.J., Zheng, X.X., Strom, T.B., Kuchroo, V.K., The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 6 (2005), 1245–1252.
15. 15•• Wu, C., Thalhamer, T., Franca, R.F., Xiao, S., Wang, C., Hotta, C., Zhu, C., Hirashima, M., Anderson, A.C., Kuchroo, V.K., Galectin-9-CD44 interaction enhances stability and function of adaptive regulatory T cells. Immunity 41 (2014), 270–282 The authors demonstrate the relevance of galectin-9 in the differentiation and stability of inducible regulatory T cells through mechanisms involving formation of CD44-TGF-βRI complexes.
16. 16 Ilarregui, J.M., Croci, D.O., Bianco, G.A., Toscano, M.A., Salatino, M., Vermeulen, M.E., Geffner, J.R., Rabinovich, G.A., Tolerogenic signals delivered by dendritic cells to T cells through a galectin-1-driven immunoregulatory circuit involving interleukin 27 and interleukin 10. Nat Immunol 10 (2009), 981–991.
17. 17 Poncini, C.V., Ilarregui, J.M., Batalla, E.I., Engels, S., Cerliani, J.P., Cucher, M.A., van Kooyk, Y., Gonzalez-Cappa, S.M., Rabinovich, G.A., Trypanosoma cruzi infection imparts a regulatory program in dendritic cells and T cells via galectin-1-dependent mechanisms. J Immunol 195 (2015), 3311–3324.
18. 18 Tesone, A.J., Rutkowski, M.R., Brencicova, E., Svoronos, N., Perales-Puchalt, A., Stephen, T.L., Allegrezza, M.J., Payne, K.K., Nguyen, J.M., Wickramasinghe, J., et al. Satb1 overexpression drives tumor-promoting activities in cancer-associated dendritic cells. Cell Rep 14 (2016), 1774–1786.
19. 19 Garin, M.I., Chu, C.C., Golshayan, D., Cernuda-Morollon, E., Wait, R., Lechler, R.I., Galectin-1: a key effector of regulation mediated by CD4 + CD25+ T cells. Blood 109 (2007), 2058–2065.
20. 20 Rubinstein, N., Alvarez, M., Zwirner, N.W., Toscano, M.A., Ilarregui, J.M., Bravo, A., Mordoh, J., Fainboim, L., Podhajcer, O.L., Rabinovich, G.A., Targeted inhibition of galectin-1 gene expression in tumor cells results in heightened T cell-mediated rejection; a potential mechanism of tumor-immune privilege. Cancer Cell 5 (2004), 241–251.
21. 21 Juszczynski, P., Ouyang, J., Monti, S., Rodig, S.J., Takeyama, K., Abramson, J., Chen, W., Kutok, J.L., Rabinovich, G.A., Shipp, M.A., The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma. Proc Natl Acad Sci U S A 104 (2007), 13134–13139.
22. 22 Kuo, P.L., Huang, M.S., Cheng, D.E., Hung, J.Y., Yang, C.J., Chou, S.H., Lung cancer-derived galectin-1 enhances tumorigenic potentiation of tumor-associated dendritic cells by expressing heparin-binding EGF-like growth factor. J Biol Chem 287 (2012), 9753–9764.
23. 23 Hsu, Y.L., Hung, J.Y., Chiang, S.Y., Jian, S.F., Wu, C.Y., Lin, Y.S., Tsai, Y.M., Chou, S.H., Tsai, M.J., Kuo, P.L., Lung cancer-derived galectin-1 contributes to cancer associated fibroblast-mediated cancer progression and immune suppression through TDO2/kynurenine axis. Oncotarget 7 (2016), 27584–27598.
24. 24• Croci, D.O., Cerliani, J.P., Dalotto-Moreno, T., Mendez-Huergo, S.P., Mascanfroni, I.D., Dergan-Dylon, S., Toscano, M.A., Caramelo, J.J., Garcia-Vallejo, J.J., Ouyang, J., et al. Glycosylation-dependent lectin–receptor interactions preserve angiogenesis in anti-VEGF refractory tumors. Cell 156 (2014), 744–758 This study defines a glycosylation-based mechanism mediated by galectin–receptor interactions that links tumor hypoxia to VEGFR2 signaling and preserves angiogenesis in settings of VEGF blockade.
25. 25 Dalotto-Moreno, T., Croci, D.O., Cerliani, J.P., Martinez-Allo, V.C., Dergan-Dylon, S., Mendez-Huergo, S.P., Stupirski, J.C., Mazal, D., Osinaga, E., Toscano, M.A., et al. Targeting galectin-1 overcomes breast cancer-associated immunosuppression and prevents metastatic disease. Cancer Res 73 (2013), 1107–1117.
26. 26 Soldati, R., Berger, E., Zenclussen, A.C., Jorch, G., Lode, H.N., Salatino, M., Rabinovich, G.A., Fest, S., Neuroblastoma triggers an immunoevasive program involving galectin-1-dependent modulation of T cell and dendritic cell compartments. Int J Cancer 131 (2012), 1131–1141.
27. 27 Baker, G.J., Chockley, P., Zamler, D., Castro, M.G., Lowenstein, P.R., Natural killer cells require monocytic Gr-1(+)/CD11b(+) myeloid cells to eradicate orthotopically engrafted glioma cells. Oncoimmunology, 5, 2016, e1163461.
28. 28• Rutkowski, M.R., Stephen, T.L., Svoronos, N., Allegrezza, M.J., Tesone, A.J., Perales-Puchalt, A., Brencicova, E., Escovar-Fadul, X., Nguyen, J.M., Cadungog, M.G., et al. Microbially driven TLR5-dependent signaling governs distal malignant progression through tumor-promoting inflammation. Cancer Cell 27 (2015), 27–40 This study identifies a regulatory circuit mediated by IL-6 and galectin-1 that links commensal microbiota, TLR5-driven systemic inflammation, immunosuppression and distal tumor growth.
29. 29 Cedeno-Laurent, F., Watanabe, R., Teague, J.E., Kupper, T.S., Clark, R.A., Dimitroff, C.J., Galectin-1 inhibits the viability, proliferation, and Th1 cytokine production of nonmalignant T cells in patients with leukemic cutaneous T-cell lymphoma. Blood 119 (2012), 3534–3538.
30. 30•• Martinez-Bosch, N., Fernandez-Barrena, M.G., Moreno, M., Ortiz-Zapater, E., Munne-Collado, J., Iglesias, M., Andre, S., Gabius, H.J., Hwang, R.F., Poirier, F., et al. Galectin-1 drives pancreatic carcinogenesis through stroma remodeling and Hedgehog signaling activation. Cancer Res 74 (2014), 3512–3524 This study explores the relevance of galectin-1 in tumor–stromal interactions within the complex microenvironment of pancreatic ductal adenocarcinoma.
31. 31 Demotte, N., Wieers, G., Van Der Smissen, P., Moser, M., Schmidt, C., Thielemans, K., Squifflet, J.L., Weynand, B., Carrasco, J., Lurquin, C., et al. A galectin-3 ligand corrects the impaired function of human CD4 and CD8 tumor-infiltrating lymphocytes and favors tumor rejection in mice. Cancer Res 70 (2010), 7476–7488.
32. 32•• Petit, A.E., Demotte, N., Scheid, B., Wildmann, C., Bigirimana, R., Gordon-Alonso, M., Carrasco, J., Valitutti, S., Godelaine, D., van der Bruggen, P., A major secretory defect of tumour-infiltrating T lymphocytes due to galectin impairing LFA-1-mediated synapse completion. Nat Commun, 7, 2016, 12242 The authors demonstrate a galectin-3-driven immune evasive mechanism leading to defects in cytokine secretion, lack of completion of secretory synapses and impaired adhesion of tumor-infiltrating lymphocytes to their targets.
33. 33 Dardalhon, V., Anderson, A.C., Karman, J., Apetoh, L., Chandwaskar, R., Lee, D.H., Cornejo, M., Nishi, N., Yamauchi, A., Quintana, F.J., et al. Tim-3/galectin-9 pathway: regulation of Th1 immunity through promotion of CD11b + Ly-6G+ myeloid cells. J Immunol 185 (2010), 1383–1392.
34. 34 Thijssen, V.L., Barkan, B., Shoji, H., Aries, I.M., Mathieu, V., Deltour, L., Hackeng, T.M., Kiss, R., Kloog, Y., Poirier, F., et al. Tumor cells secrete galectin-1 to enhance endothelial cell activity. Cancer Res 70 (2010), 6216–6224.
35. 35 Markowska, A.I., Jefferies, K.C., Panjwani, N., Galectin-3 protein modulates cell surface expression and activation of vascular endothelial growth factor receptor 2 in human endothelial cells. J Biol Chem 286 (2011), 29913–29921.
36. 36 Laderach, D.J., Gentilini, L.D., Giribaldi, L., Delgado, V.C., Nugnes, L., Croci, D.O., Al Nakouzi, N., Sacca, P., Casas, G., Mazza, O., et al. A unique galectin signature in human prostate cancer progression suggests galectin-1 as a key target for treatment of advanced disease. Cancer Res 73 (2013), 86–96.
37. 37 Croci, D.O., Salatino, M., Rubinstein, N., Cerliani, J.P., Cavallin, L.E., Leung, H.J., Ouyang, J., Ilarregui, J.M., Toscano, M.A., Domaica, C.I., et al. Disrupting galectin-1 interactions with N-glycans suppresses hypoxia-driven angiogenesis and tumorigenesis in Kaposi's sarcoma. J Exp Med 209 (2012), 1985–2000.
38. 38 Liu, S.D., Tomassian, T., Bruhn, K.W., Miller, J.F., Poirier, F., Miceli, M.C., Galectin-1 tunes TCR binding and signal transduction to regulate CD8 burst size. J Immunol 182 (2009), 5283–5295.
39. 39 Demetriou, M., Granovsky, M., Quaggin, S., Dennis, J.W., Negative regulation of T-cell activation and autoimmunity by Mgat5 N-glycosylation. Nature 409 (2001), 733–739.
40. 40 Chen, I.J., Chen, H.L., Demetriou, M., Lateral compartmentalization of T cell receptor versus CD45 by galectin-N-glycan binding and microfilaments coordinate basal and activation signaling. J Biol Chem 282 (2007), 35361–35372.
41. 41 Demotte, N., Stroobant, V., Courtoy, P.J., Van Der Smissen, P., Colau, D., Luescher, I.F., Hivroz, C., Nicaise, J., Squifflet, J.L., Mourad, M., et al. Restoring the association of the T cell receptor with CD8 reverses anergy in human tumor-infiltrating lymphocytes. Immunity 28 (2008), 414–424.
42. 42 Chen, H.Y., Fermin, A., Vardhana, S., Weng, I.C., Lo, K.F., Chang, E.Y., Maverakis, E., Yang, R.Y., Hsu, D.K., Dustin, M.L., et al. Galectin-3 negatively regulates TCR-mediated CD4+ T-cell activation at the immunological synapse. Proc Natl Acad Sci U S A 106 (2009), 14496–14501.
43. 43 Rangachari, M., Zhu, C., Sakuishi, K., Xiao, S., Karman, J., Chen, A., Angin, M., Wakeham, A., Greenfield, E.A., Sobel, R.A., et al. Bat3 promotes T cell responses and autoimmunity by repressing Tim-3-mediated cell death and exhaustion. Nat Med 18 (2012), 1394–1400.
44. 44 Matarrese, P., Tinari, A., Mormone, E., Bianco, G.A., Toscano, M.A., Ascione, B., Rabinovich, G.A., Malorni, W., Galectin-1 sensitizes resting human T lymphocytes to Fas (CD95)-mediated cell death via mitochondrial hyperpolarization, budding, and fission. J Biol Chem 280 (2005), 6969–6985.
45. 45 Toscano, M.A., Bianco, G.A., Ilarregui, J.M., Croci, D.O., Correale, J., Hernandez, J.D., Zwirner, N.W., Poirier, F., Riley, E.M., Baum, L.G., et al. Differential glycosylation of TH1, TH2 and TH-17 effector cells selectively regulates susceptibility to cell death. Nat Immunol 8 (2007), 825–834.
46. 46 Oomizu, S., Arikawa, T., Niki, T., Kadowaki, T., Ueno, M., Nishi, N., Yamauchi, A., Hirashima, M., Galectin-9 suppresses Th17 cell development in an IL-2-dependent but Tim-3-independent manner. Clin Immunol 143 (2012), 51–58.
47. 47 Kang, C.W., Dutta, A., Chang, L.Y., Mahalingam, J., Lin, Y.C., Chiang, J.M., Hsu, C.Y., Huang, C.T., Su, W.T., Chu, Y.Y., et al. Apoptosis of tumor infiltrating effector TIM-3 + CD8+ T cells in colon cancer. Sci Rep, 5, 2015, 15659.
48. 48 Su, E.W., Bi, S., Kane, L.P., Galectin-9 regulates T helper cell function independently of Tim-3. Glycobiology 21 (2011), 1258–1265.
49. 49 Deak, M., Hornung, A., Novak, J., Demydenko, D., Szabo, E., Czibula, A., Fajka-Boja, R., Kriston-Pal, E., Monostori, E., Kovacs, L., Novel role for galectin-1 in T-cells under physiological and pathological conditions. Immunobiology 220 (2015), 483–489.
50. 50 Yang, R.Y., Hsu, D.K., Liu, F.T., Expression of galectin-3 modulates T-cell growth and apoptosis. Proc Natl Acad Sci U S A 93 (1996), 6737–6742.
51. 51 Kubach, J., Lutter, P., Bopp, T., Stoll, S., Becker, C., Huter, E., Richter, C., Weingarten, P., Warger, T., Knop, J., et al. Human CD4 + CD25+ regulatory T cells: proteome analysis identifies galectin-10 as a novel marker essential for their anergy and suppressive function. Blood 110 (2007), 1550–1558.
52. 52 Toscano, M.A., Commodaro, A.G., Ilarregui, J.M., Bianco, G.A., Liberman, A., Serra, H.M., Hirabayashi, J., Rizzo, L.V., Rabinovich, G.A., Galectin-1 suppresses autoimmune retinal disease by promoting concomitant Th2- and T regulatory-mediated anti-inflammatory responses. J Immunol 176 (2006), 6323–6332.
53. 53 Blois, S.M., Ilarregui, J.M., Tometten, M., Garcia, M., Orsal, A.S., Cordo-Russo, R., Toscano, M.A., Bianco, G.A., Kobelt, P., Handjiski, B., et al. A pivotal role for galectin-1 in fetomaternal tolerance. Nat Med 13 (2007), 1450–1457.
54. 54 Cedeno-Laurent, F., Opperman, M., Barthel, S.R., Kuchroo, V.K., Dimitroff, C.J., Galectin-1 triggers an immunoregulatory signature in Th cells functionally defined by IL-10 expression. J Immunol 188 (2012), 3127–3137.
55. 55 Sampson, J.F., Suryawanshi, A., Chen, W.S., Rabinovich, G.A., Panjwani, N., Galectin-8 promotes regulatory T-cell differentiation by modulating IL-2 and TGFbeta signaling. Immunol Cell Biol 94 (2016), 213–219.
56. 56 Jiang, H.R., Al Rasebi, Z., Mensah-Brown, E., Shahin, A., Xu, D., Goodyear, C.S., Fukada, S.Y., Liu, F.T., Liew, F.Y., Lukic, M.L., Galectin-3 deficiency reduces the severity of experimental autoimmune encephalomyelitis. J Immunol 182 (2009), 1167–1173.
57. 57 Fermino, M.L., Dias, F.C., Lopes, C.D., Souza, M.A., Cruz, A.K., Liu, F.T., Chammas, R., Roque-Barreira, M.C., Rabinovich, G.A., Bernardes, E.S., Galectin-3 negatively regulates the frequency and function of CD4(+) CD25(+) Foxp3(+) regulatory T cells and influences the course of Leishmania major infection. Eur J Immunol 43 (2013), 1806–1817.
58. 58 Mari, E.R., Rasouli, J., Ciric, B., Moore, J.N., Conejo-Garcia, J.R., Rajasagi, N., Zhang, G.X., Rabinovich, G.A., Rostami, A., Galectin-1 is essential for the induction of MOG35-55-based intravenous tolerance in experimental autoimmune encephalomyelitis. Eur J Immunol 46 (2016), 1783–1796.
59. 59•• Thiemann, S., Man, J.H., Chang, M.H., Lee, B., Baum, L.G., Galectin-1 regulates tissue exit of specific dendritic cell populations. J Biol Chem 290 (2015), 22662–22677 The authors report a glycosylation-based mechanism by which galectin-1 selectively inhibits tissue emigration of immunogenic, but not tolerogenic, dendritic cells.
60. 60 Barrionuevo, P., Beigier-Bompadre, M., Ilarregui, J.M., Toscano, M.A., Bianco, G.A., Isturiz, M.A., Rabinovich, G.A., A novel function for galectin-1 at the crossroad of innate and adaptive immunity: galectin-1 regulates monocyte/macrophage physiology through a nonapoptotic ERK-dependent pathway. J Immunol 178 (2007), 436–445.
61. 61 Rostoker, R., Yaseen, H., Schif-Zuck, S., Lichtenstein, R.G., Rabinovich, G.A., Ariel, A., Galectin-1 induces 12/15-lipoxygenase expression in murine macrophages and favors their conversion toward a pro-resolving phenotype. Prostaglandins Other Lipid Mediat 107 (2013), 85–94.
62. 62 Verschuere, T., Toelen, J., Maes, W., Poirier, F., Boon, L., Tousseyn, T., Mathivet, T., Gerhardt, H., Mathieu, V., Kiss, R., et al. Glioma-derived galectin-1 regulates innate and adaptive antitumor immunity. Int J Cancer 134 (2014), 873–884.
63. 63 Partridge, E.A., Le Roy, C., Di Guglielmo, G.M., Pawling, J., Cheung, P., Granovsky, M., Nabi, I.R., Wrana, J.L., Dennis, J.W., Regulation of cytokine receptors by Golgi N-glycan processing and endocytosis. Science 306 (2004), 120–124.
64. 64 Tsuboi, S., Sutoh, M., Hatakeyama, S., Hiraoka, N., Habuchi, T., Horikawa, Y., Hashimoto, Y., Yoneyama, T., Mori, K., Koie, T., et al. A novel strategy for evasion of NK cell immunity by tumours expressing core2 O-glycans. EMBO J 30 (2011), 3173–3185.
65. 65 Wang, W., Guo, H., Geng, J., Zheng, X., Wei, H., Sun, R., Tian, Z., Tumor-released Galectin-3, a soluble inhibitory ligand of human NKp30, plays an important role in tumor escape from NK cell attack. J Biol Chem 289 (2014), 33311–33319.
66. 66 Golden-Mason, L., McMahan, R.H., Strong, M., Reisdorph, R., Mahaffey, S., Palmer, B.E., Cheng, L., Kulesza, C., Hirashima, M., Niki, T., et al. Galectin-9 functionally impairs natural killer cells in humans and mice. J Virol 87 (2013), 4835–4845.
67. 67 Motz, G.T., Coukos, G., The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat Rev Immunol 11 (2011), 702–711.
68. 68 Corzo, C.A., Condamine, T., Lu, L., Cotter, M.J., Youn, J.I., Cheng, P., Cho, H.I., Celis, E., Quiceno, D.G., Padhya, T., et al. HIF-1alpha regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J Exp Med 207 (2010), 2439–2453.
69. 69 Bax, M., Garcia-Vallejo, J.J., Jang-Lee, J., North, S.J., Gilmartin, T.J., Hernandez, G., Crocker, P.R., Leffler, H., Head, S.R., Haslam, S.M., et al. Dendritic cell maturation results in pronounced changes in glycan expression affecting recognition by siglecs and galectins. J Immunol 179 (2007), 8216–8224.
70. 70 Markowska, A.I., Liu, F.T., Panjwani, N., Galectin-3 is an important mediator of VEGF- and bFGF-mediated angiogenic response. J Exp Med 207 (2010), 1981–1993.
71. 71 Machado, C.M., Andrade, L.N., Teixeira, V.R., Costa, F.F., Melo, C.M., dos Santos, S.N., Nonogaki, S., Liu, F.T., Bernardes, E.S., Camargo, A.A., et al. Galectin-3 disruption impaired tumoral angiogenesis by reducing VEGF secretion from TGFbeta1-induced macrophages. Cancer Med 3 (2014), 201–214.
72. 72 Delgado, V.M., Nugnes, L.G., Colombo, L.L., Troncoso, M.F., Fernandez, M.M., Malchiodi, E.L., Frahm, I., Croci, D.O., Compagno, D., Rabinovich, G.A., et al. Modulation of endothelial cell migration and angiogenesis: a novel function for the tandem-repeat lectin galectin-8. FASEB J 25 (2011), 242–254.
73. 73•• Chen, W.S., Cao, Z., Sugaya, S., Lopez, M.J., Sendra, V.G., Laver, N., Leffler, H., Nilsson, U.J., Fu, J., Song, J., et al. Pathological lymphangiogenesis is modulated by galectin-8-dependent crosstalk between podoplanin and integrin-associated VEGFR-3. Nat Commun, 7, 2016, 11302 The authors report a galectin-8-driven pathway that controls lymphangiogenesis and links VEGF-C, podoplanin and α1β1 and α5β1 integrins.
74. 74 Heusschen, R., Schulkens, I.A., van Beijnum, J., Griffioen, A.W., Thijssen, V.L., Endothelial LGALS9 splice variant expression in endothelial cell biology and angiogenesis. Biochim Biophys Acta 1842 (2014), 284–292.
75. 75•• Lykken, J.M., Horikawa, M., Minard-Colin, V., Kamata, M., Miyagaki, T., Poe, J.C., Tedder, T.F., Galectin-1 drives lymphoma CD20 immunotherapy resistance: validation of a preclinical system to identify resistance mechanisms. Blood 127 (2016), 1886–1895 This study highlights the role of galectin-1 as a mechanism of resistance to anti-CD20 (rituximab) immunotherapy via regulation of antibody-mediated lymphoma phagocytosis.
76. 76 Luo, W., Song, L., Chen, X.L., Zeng, X.F., Wu, J.Z., Zhu, C.R., Huang, T., Tan, X.P., Lin, X.M., Yang, Q., et al. Identification of galectin-1 as a novel mediator for chemoresistance in chronic myeloid leukemia cells. Oncotarget 7 (2016), 26709–26723.
77. 77 Kuo, P., Bratman, S.V., Shultz, D.B., von Eyben, R., Chan, C., Wang, Z., Say, C., Gupta, A., Loo, B.W. Jr., Giaccia, A.J., et al. Galectin-1 mediates radiation-related lymphopenia and attenuates NSCLC radiation response. Clin Cancer Res 20 (2014), 5558–5569.
78. 78 Yamamoto-Sugitani, M., Kuroda, J., Ashihara, E., Nagoshi, H., Kobayashi, T., Matsumoto, Y., Sasaki, N., Shimura, Y., Kiyota, M., Nakayama, R., et al. Galectin-3 (Gal-3) induced by leukemia microenvironment promotes drug resistance and bone marrow lodgment in chronic myelogenous leukemia. Proc Natl Acad Sci U S A 108 (2011), 17468–17473.
79. 79 Harazono, Y., Kho, D.H., Balan, V., Nakajima, K., Hogan, V., Raz, A., Extracellular galectin-3 programs multidrug resistance through Na+/K+-ATPase and P-glycoprotein signaling. Oncotarget 6 (2015), 19592–19604.
80. 80 Cagnoni, A.J., Perez Saez, J.M., Rabinovich, G.A., Marino, K.V., Turning-off signaling by siglecs selectins, and galectins: chemical inhibition of glycan-dependent interactions in cancer. Front Oncol, 6, 2016, 109.